NASDAQ:XNCR - Xencor Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $36.12 -1.80 (-4.75 %) (As of 12/17/2018 01:39 AM ET)Previous Close$36.12Today's Range$35.85 - $37.7552-Week Range$20.16 - $48.38Volume172,383 shsAverage Volume149,540 shsMarket Capitalization$2.03 billionP/E Ratio-34.40Dividend YieldN/ABeta1.79 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug, that in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; and AMG424, a bispecific CD38 x CD3 preclinical candidate for various myeloma. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104, which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to develop and commercialize bispecific and other Fc engineered antibody drug candidates using its proprietary XmAb technologies and drug candidates, as well as MorphoSys Ag to develop and commercialize bispecific antibody product candidates; license agreement with Amgen Inc. to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc.was founded in 1997 and is headquartered in Monrovia, California. Receive XNCR News and Ratings via Email Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XNCR Previous Symbol CUSIPN/A Webwww.xencor.com Phone626-305-5900 Debt Debt-to-Equity RatioN/A Current Ratio5.52 Quick Ratio5.52 Price-To-Earnings Trailing P/E Ratio-34.40 Forward P/E Ratio-23.61 P/E GrowthN/A Sales & Book Value Annual Sales$35.71 million Price / Sales56.88 Cash FlowN/A Price / Cash FlowN/A Book Value$6.01 per share Price / Book6.01 Profitability EPS (Most Recent Fiscal Year)($1.05) Net Income$-48,920,000.00 Net MarginsN/A Return on Equity-13.69% Return on Assets-11.76% Miscellaneous Employees114 Outstanding Shares56,230,000Market Cap$2.03 billion OptionableOptionable Xencor (NASDAQ:XNCR) Frequently Asked Questions What is Xencor's stock symbol? Xencor trades on the NASDAQ under the ticker symbol "XNCR." How were Xencor's earnings last quarter? Xencor Inc (NASDAQ:XNCR) posted its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.52) by $0.57. The biopharmaceutical company had revenue of $29.04 million for the quarter. View Xencor's Earnings History. When is Xencor's next earnings date? Xencor is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Xencor. What price target have analysts set for XNCR? 7 brokers have issued 1-year target prices for Xencor's stock. Their predictions range from $28.00 to $56.00. On average, they expect Xencor's share price to reach $41.50 in the next year. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Price Targets for Xencor. What is the consensus analysts' recommendation for Xencor? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor. What are Wall Street analysts saying about Xencor stock? Here are some recent quotes from research analysts about Xencor stock: 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (12/15/2018) 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and are adjusting our PT to $40 from $37 for XNCR stock. We believe the company’s Fc-engineering know-how will produce abundant drug candidates with which to populate XNCR’s proprietary pipeline as well as partnering opportunities as needed. As with most so-called technology platform companies, we believe proof of concept/commercial potential would compel investors to ascribe some value to assets the identity/ characteristics of which have not yet been revealed." (11/6/2018) Has Xencor been receiving favorable news coverage? News headlines about XNCR stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xencor earned a news impact score of 1.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are some of Xencor's key competitors? Some companies that are related to Xencor include Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE) and United Therapeutics (UTHR). Who are Xencor's key executives? Xencor's management team includes the folowing people: Dr. Bassil I. Dahiyat, Co-Founder, CEO, Pres & Director (Age 48)Mr. John J. Kuch, Sr. VP, CFO & Sec. (Age 59)Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 54)Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 64)Dr. Debra Zack M.D., Ph.D., VP of Clinical Devel. Who are Xencor's major shareholders? Xencor's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.89%), Primecap Management Co. CA (13.55%), Vanguard Group Inc. (7.46%), Vanguard Group Inc (7.46%), BlackRock Inc. (7.21%) and Redmile Group LLC (5.39%). Company insiders that own Xencor stock include Bassil I Dahiyat, Bruce L A Carter, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor. Which major investors are selling Xencor stock? XNCR stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Perceptive Advisors LLC, Redmile Group LLC, Prudential Financial Inc., First Light Asset Management LLC, Franklin Resources Inc., Moody Aldrich Partners LLC and Bank of New York Mellon Corp. Company insiders that have sold Xencor company stock in the last year include Bassil I Dahiyat, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Insider Buying and Selling for Xencor. Which major investors are buying Xencor stock? XNCR stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., Artal Group S.A., Loomis Sayles & Co. L P, Primecap Management Co. CA, BlackRock Inc., Dimensional Fund Advisors LP and Point72 Asset Management L.P.. View Insider Buying and Selling for Xencor. How do I buy shares of Xencor? Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Xencor's stock price today? One share of XNCR stock can currently be purchased for approximately $36.12. How big of a company is Xencor? Xencor has a market capitalization of $2.03 billion and generates $35.71 million in revenue each year. The biopharmaceutical company earns $-48,920,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Xencor employs 114 workers across the globe. What is Xencor's official website? The official website for Xencor is http://www.xencor.com. How can I contact Xencor? Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected] MarketBeat Community Rating for Xencor (NASDAQ XNCR)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 342 (Vote Outperform)Underperform Votes: 192 (Vote Underperform)Total Votes: 534MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?